ReviewTrends in cognitive sciences2015
How Schizophrenia Develops: Cognitive and Brain Mechanisms Underlying Onset of Psychosis.
Review in Trends in cognitive sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 102 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
102 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Linking Inflammation, Aberrant Glutamate-Dopamine Interaction, and Post-synaptic Changes: Translational Relevance for Schizophrenia and Antipsychotic Treatment: a Systematic Review.Molecular neurobiology · 2022Pooled it
- Thalamic dopamine D2-receptor availability in schizophrenia: a study on antipsychotic-naive patients with first-episode psychosis and a meta-analysis.Molecular psychiatry · 2022Pooled it
- Cerebellar gray matter volume changes in patients with schizophrenia: A voxel-based meta-analysis.Frontiers in psychiatry · 2022Pooled it
- The role of C957T, TaqI and Ser311Cys polymorphisms of the DRD2 gene in schizophrenia: systematic review and meta-analysis.Behavioral and brain functions : BBF · 2016Pooled it
- Validation of ketamine as a pharmacological model of thalamic dysconnectivity across the illness course of schizophrenia.Molecular psychiatry · 2022Trial
- Schizophrenia: from mechanism to therapy.Science China. Life sciences · 2026Review
- Functional genomic profiling of schizophrenia-associated genes reveals key microglial regulators.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Serum proteomic signatures and an immune-calcium signaling cascade associated with antipsychotic-related erectile dysfunction in schizophrenia.Scientific reports · 2026Article
- Rethinking language, cognition and assessment in psychosis: How bilingualism challenges psychiatry and how natural language processing can help.Schizophrenia (Heidelberg, Germany) · 2026Review
- Compensatory hallucinogenesis across three neuropsychiatric disorders: a Bayesian account.Brain communications · 2026Review
- Article
- Functional Genomic Profiling of Schizophrenia-Associated Genes Reveals Key Microglial Regulators.bioRxiv : the preprint server for biology · 2025Article
- Molecular Underpinning of Treatment-Resistant Schizophrenia: A Putative Different Neurobiology from Treatment-Responsive Schizophrenia.International journal of molecular sciences · 2025Review
- Cell-free DNA in extracellular vesicles: A candidate biomarker of schizophrenia.World journal of psychiatry · 2025Review
- The influence of deprivation on cortical development and psychotic symptoms in youth.Journal of child psychology and psychiatry, and allied disciplines · 2025Article
- The awareness, characterization, and burden of Cognitive Impairment Associated with Schizophrenia (CIAS) in clinical practice: Results from a nationwide survey in Italy.Schizophrenia research. Cognition · 2025Article
- Reward Processing in Mood Disorders and Schizophrenia: A Neurodevelopmental Framework.Annual review of clinical psychology · 2025Review
- Brain Markers of Resilience to Psychosis in High-Risk Individuals: A Systematic Review and Label-Based Meta-Analysis of Multimodal MRI Studies.Brain sciences · 2025Review
- Brain Age Gap in Early Illness Schizophrenia and the Clinical High-Risk Syndrome: Associations With Experiential Negative Symptoms and Conversion to Psychosis.Schizophrenia bulletin · 2024Article
- Nicotine's Effects on Schizophrenia-like Symptoms in a Mice Model: Time Matters.Brain sciences · 2024Article
42 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Identifying cognitive and neural mechanisms involved in the development of schizophrenia requires longitudinal observation of individuals prior to onset. Here recent studies of prodromal individuals who progress to full psychosis are briefly reviewed in relation to models of schizophrenia pathophysiology. Together, this body of work suggests that disruption in brain connectivity, driven primarily by a progressive reduction in dendritic spines on cortical pyramidal neurons, may represent a key triggering mechanism. The earliest disruptions appear to be in circuits involved in referencing experiences according to time, place, and agency, which may result in a failure to recognize particular cognitions as self-generated or to constrain interpretations of the meaning of events based on prior experiences, providing the scaffolding for faulty reality testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.